Prelude Therapeutics Inc’s net profit fell -11.17% since last year same period to $-30.43Mn in the Q2 2023. On a quarterly growth basis, Prelude Therapeutics Inc has generated -15.61% fall in its net profits since last 3-months.
EPS Estimate Current Quarter
EPS Estimate Current Year
Prelude Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.63 - a 1.56% jump from last quarter’s estimates.
Prelude Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.63.
Return on Assets (ROA)
Return on Equity (ROE)
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Prelude Therapeutics Inc’s return on assets (ROA) stands at -0.29.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Prelude Therapeutics Inc’s return on equity (ROE) stands at -0.46.
|Earnings Date||Estimated EPS||Reported EPS||Surprise %|